337 related articles for article (PubMed ID: 34344693)
21. MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis.
Khan P; Siddiqui JA; Kshirsagar PG; Venkata RC; Maurya SK; Mirzapoiazova T; Perumal N; Chaudhary S; Kanchan RK; Fatima M; Khan MA; Rehman AU; Lakshmanan I; Mahapatra S; Talmon GA; Kulkarni P; Ganti AK; Jain M; Salgia R; Batra SK; Nasser MW
Mol Cancer; 2023 Jan; 22(1):1. PubMed ID: 36597126
[TBL] [Abstract][Full Text] [Related]
22. RET mutation and expression in small-cell lung cancer.
Dabir S; Babakoohi S; Kluge A; Morrow JJ; Kresak A; Yang M; MacPherson D; Wildey G; Dowlati A
J Thorac Oncol; 2014 Sep; 9(9):1316-23. PubMed ID: 25122427
[TBL] [Abstract][Full Text] [Related]
23. MAX Functions as a Tumor Suppressor and Rewires Metabolism in Small Cell Lung Cancer.
Augert A; Mathsyaraja H; Ibrahim AH; Freie B; Geuenich MJ; Cheng PF; Alibeckoff SP; Wu N; Hiatt JB; Basom R; Gazdar A; Sullivan LB; Eisenman RN; MacPherson D
Cancer Cell; 2020 Jul; 38(1):97-114.e7. PubMed ID: 32470392
[TBL] [Abstract][Full Text] [Related]
24. Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
Tenjin Y; Kudoh S; Kubota S; Yamada T; Matsuo A; Sato Y; Ichimura T; Kohrogi H; Sashida G; Sakagami T; Ito T
Lab Invest; 2019 Nov; 99(11):1622-1635. PubMed ID: 31231131
[TBL] [Abstract][Full Text] [Related]
25. MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.
Mollaoglu G; Guthrie MR; Böhm S; Brägelmann J; Can I; Ballieu PM; Marx A; George J; Heinen C; Chalishazar MD; Cheng H; Ireland AS; Denning KE; Mukhopadhyay A; Vahrenkamp JM; Berrett KC; Mosbruger TL; Wang J; Kohan JL; Salama ME; Witt BL; Peifer M; Thomas RK; Gertz J; Johnson JE; Gazdar AF; Wechsler-Reya RJ; Sos ML; Oliver TG
Cancer Cell; 2017 Feb; 31(2):270-285. PubMed ID: 28089889
[TBL] [Abstract][Full Text] [Related]
26. MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate.
Ireland AS; Micinski AM; Kastner DW; Guo B; Wait SJ; Spainhower KB; Conley CC; Chen OS; Guthrie MR; Soltero D; Qiao Y; Huang X; Tarapcsák S; Devarakonda S; Chalishazar MD; Gertz J; Moser JC; Marth G; Puri S; Witt BL; Spike BT; Oliver TG
Cancer Cell; 2020 Jul; 38(1):60-78.e12. PubMed ID: 32473656
[TBL] [Abstract][Full Text] [Related]
27. CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer.
Ng SR; Rideout WM; Akama-Garren EH; Bhutkar A; Mercer KL; Schenkel JM; Bronson RT; Jacks T
Proc Natl Acad Sci U S A; 2020 Jan; 117(1):513-521. PubMed ID: 31871154
[TBL] [Abstract][Full Text] [Related]
28. Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer.
Iwakawa R; Takenaka M; Kohno T; Shimada Y; Totoki Y; Shibata T; Tsuta K; Nishikawa R; Noguchi M; Sato-Otsubo A; Ogawa S; Yokota J
Genes Chromosomes Cancer; 2013 Sep; 52(9):802-16. PubMed ID: 23716474
[TBL] [Abstract][Full Text] [Related]
29. Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer.
Ding X; Shi MX; Liu D; Cao JX; Zhang KX; Zhang RD; Zhang LP; Ai KX; Su B; Zhang J
Cell Commun Signal; 2024 Jan; 22(1):45. PubMed ID: 38233864
[TBL] [Abstract][Full Text] [Related]
30. Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer.
Jahchan NS; Lim JS; Bola B; Morris K; Seitz G; Tran KQ; Xu L; Trapani F; Morrow CJ; Cristea S; Coles GL; Yang D; Vaka D; Kareta MS; George J; Mazur PK; Nguyen T; Anderson WC; Dylla SJ; Blackhall F; Peifer M; Dive C; Sage J
Cell Rep; 2016 Jul; 16(3):644-56. PubMed ID: 27373157
[TBL] [Abstract][Full Text] [Related]
31. Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer.
Hong D; Knelson EH; Li Y; Durmaz YT; Gao W; Walton E; Vajdi A; Thai T; Sticco-Ivins M; Sabet AH; Jones KL; Schinzel AC; Bronson RT; Nguyen QD; Tolstorukov MY; Vivero M; Signoretti S; Barbie DA; Oser MG
Cancer Res; 2022 Jan; 82(2):248-263. PubMed ID: 34810201
[TBL] [Abstract][Full Text] [Related]
32. ASCL1 represses a SOX9
Olsen RR; Ireland AS; Kastner DW; Groves SM; Spainhower KB; Pozo K; Kelenis DP; Whitney CP; Guthrie MR; Wait SJ; Soltero D; Witt BL; Quaranta V; Johnson JE; Oliver TG
Genes Dev; 2021 Jun; 35(11-12):847-869. PubMed ID: 34016693
[TBL] [Abstract][Full Text] [Related]
33. Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients.
Semenova EA; Kwon MC; Monkhorst K; Song JY; Bhaskaran R; Krijgsman O; Kuilman T; Peters D; Buikhuisen WA; Smit EF; Pritchard C; Cozijnsen M; van der Vliet J; Zevenhoven J; Lambooij JP; Proost N; van Montfort E; Velds A; Huijbers IJ; Berns A
Cell Rep; 2016 Jul; 16(3):631-43. PubMed ID: 27373156
[TBL] [Abstract][Full Text] [Related]
34. MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer.
Dammert MA; Brägelmann J; Olsen RR; Böhm S; Monhasery N; Whitney CP; Chalishazar MD; Tumbrink HL; Guthrie MR; Klein S; Ireland AS; Ryan J; Schmitt A; Marx A; Ozretić L; Castiglione R; Lorenz C; Jachimowicz RD; Wolf E; Thomas RK; Poirier JT; Büttner R; Sen T; Byers LA; Reinhardt HC; Letai A; Oliver TG; Sos ML
Nat Commun; 2019 Aug; 10(1):3485. PubMed ID: 31375684
[TBL] [Abstract][Full Text] [Related]
35. Complex intrachromosomal rearrangement in the process of amplification of the L-myc gene in small-cell lung cancer.
Sekido Y; Takahashi T; Mäkelä TP; Obata Y; Ueda R; Hida T; Hibi K; Shimokata K; Alitalo K; Takahashi T
Mol Cell Biol; 1992 Apr; 12(4):1747-54. PubMed ID: 1312669
[TBL] [Abstract][Full Text] [Related]
36. A fusion protein formed by L-myc and a novel gene in SCLC.
Mäkelä TP; Saksela K; Evan G; Alitalo K
EMBO J; 1991 Jun; 10(6):1331-5. PubMed ID: 1851085
[TBL] [Abstract][Full Text] [Related]
37. Advances in Small-Cell Lung Cancer (SCLC) Translational Research.
Drapkin BJ; Rudin CM
Cold Spring Harb Perspect Med; 2021 Apr; 11(4):. PubMed ID: 32513672
[TBL] [Abstract][Full Text] [Related]
38. WNT5A-RHOA Signaling Is a Driver of Tumorigenesis and Represents a Therapeutically Actionable Vulnerability in Small Cell Lung Cancer.
Kim KB; Kim DW; Kim Y; Tang J; Kirk N; Gan Y; Kim B; Fang B; Park JL; Zheng Y; Park KS
Cancer Res; 2022 Nov; 82(22):4219-4233. PubMed ID: 36102736
[TBL] [Abstract][Full Text] [Related]
39. MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.
Chen J; Guanizo AC; Jakasekara WSN; Inampudi C; Luong Q; Garama DJ; Alamgeer M; Thakur N; DeVeer M; Ganju V; Watkins DN; Cain JE; Gough DJ
J Exp Clin Cancer Res; 2023 Apr; 42(1):100. PubMed ID: 37098540
[TBL] [Abstract][Full Text] [Related]
40. Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes.
Pongor LS; Schultz CW; Rinaldi L; Wangsa D; Redon CE; Takahashi N; Fialkoff G; Desai P; Zhang Y; Burkett S; Hermoni N; Vilk N; Gutin J; Gergely R; Zhao Y; Nichols S; Vilimas R; Sciuto L; Graham C; Caravaca JM; Turan S; Tsai-Wei S; Rajapakse VN; Kumar R; Upadhyay D; Kumar S; Kim YS; Roper N; Tran B; Hewitt SM; Kleiner DE; Aladjem MI; Friedman N; Hager GL; Pommier Y; Ried T; Thomas A
Cancer Discov; 2023 Apr; 13(4):928-949. PubMed ID: 36715552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
